Table 2. Summary of assay positivity and assay format agreement.
| Antigen | Cohort | Assay format | Sensitivity (%) | Specificity (%) | Concordance (%) |
| p53 BirA | 1 | HTPA | 34 | 100 | 100 |
| R&D EarlyCDT | 34 | 100 | |||
| GBU4-5 BirA* | 1 | HTPA | 13 | 94 | 96 |
| R&D EarlyCDT | 9 | 100 | |||
| p53 BirA | 2 | HTPA | 15 | 98 | 95 |
| R&D EarlyCDT | 14 | 95 | |||
| CAGE BirA | 2 | HTPA | 10 | 97 | 95 |
| R&D EarlyCDT | 10 | 96 | |||
| SOX2 BirA | 2 | HTPA | 4 | 100 | 99 |
| R&D EarlyCDT | 3 | 100 | |||
| NY-ESO-1 | 2 | HTPA | 21 | 97 | 95 |
| BirA | R&D EarlyCDT | 22 | 97 | ||
| GBU4-5 BirA | 2 | HTPA | 5 | 95 | 97 |
| R&D EarlyCDT | 5 | 96 | |||
| HuD BirA | 2 | HTPA | 4 | 98 | 98 |
| R&D EarlyCDT | 4 | 98 | |||
| MAGE A4 | 2 | HTPA | 10 | 96 | 96 |
| BirA | R&D EarlyCDT | 10 | 95 |
Comparison of HTPA and R&D EarlyCDT sample positivity results for commercial batches of certain lung panel antigens for Cohorts 1 and 2. * GBU4-5 compares an R&D batch (HTPA) to a commercial batch (R&D EarlyCDT), expressed under different conditions.